时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
One of the major challenges in cancer treatment is overcoming drug resistance, which can develop even in patients with a good original response to therapy (; ; ).；However, TP53 status cannot be considered as a stand-alone predictor of response to PP2A inhibition.；The central translational question is whether transient PP2A inhibition can be confined to a therapeutic corridor that enhances tumor-cell vulnerability while preserving PP2A-dependent homeostasis in normal tissues, particularly the nervous system.
方法
A systematic review of 60 patients from 16 studies identified 26 pathogenic variants, predominantly de novo heterozygous missense mutations clustering in HEAT repeats 5–7.；FTY720 (Fingolimod), the FDA-approved multiple sclerosis drug, binds SET, which is an endogenous PP2A inhibitor, blocking the SET–PP2A-C interaction and driving SET nuclear translocation away from cytoplasmic PP2A ().；In the phase 0 window-of-opportunity study in recurrent gliomas, intact LB100 concentration in resected tumor tissue averaged 0.31% of the matched plasma concentration and was approximately 1,000-fold below the reported PP2A-inhibitory IC50 ().
核心结论
A short, treatment-timed inhibitory pulse may impair these recovery processes, promote inappropriate mitotic entry in the presence of incompletely repaired DNA, and increase mitotic catastrophe or apoptosis (; ; ; ; ).；Possible determinants include high replication stress, chromosomal instability, defective homologous-recombination repair, and dependence on WEE1/CHK1/PLK1 or ATM/ATR signaling (; ; ; ).；This framework also makes safety central, because PP2A has essential physiological functions, particularly in the nervous system, where sustained dysfunction is associated with neurodevelopmental disorders and neurodegeneration (; ; ; ). ‖ 结论：The value of PP2A/PP5 inhibition is therefore unlikely to lie in sustained systemic phosphatase suppression, but rather in short, quantifiable, and tumor-informed perturbation of stress-adaptation pathways within combination regimens.
局限
Future studies should prioritize paired tumor–plasma pharmacokinetics, separate measurement of LB100 and endothall, direct pharmacodynamic evidence of PP2A/PP5 modulation, schedule optimization, and biomarker-guided patient selection.
对本项目的价值
★☆☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
全文来源
PMC JATS 全文（正文 66,564 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：PP2A targeting: balancing anticancer potential and neurological risk.
- 期刊与标识：Front Cell Dev Biol · PMID 42947971 · DOI 10.3389/fcell.2026.1945801
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。